Study on patients’ medicine instruction regulatory system in the European Union and the enlightenment

YUAN Sihan; JIANG Rong; ZHENG Yujie; LI Haiqi; CHEN Yixuan; SHAO Rong

doi:10.6039/j.issn.1001-0408.2025.03.02

您当前的位置：

首页 >

文章列表页 >

Study on patients’ medicine instruction regulatory system in the European Union and the enlightenment

更新时间：2025-09-26

- Study on patients’ medicine instruction regulatory system in the European Union and the enlightenment
- ZHONGGUO YAOFANG Vol. 36, Issue 3, Pages: 269-274(2025)
- 作者机构：
  
  中国药科大学药品监管科学研究院，南京　211198
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2025.03.02
  CLC： R95
- Received：13 August 2024，
  
  Revised：2024-12-09，
  
  Accepted：10 December 2024，
  
  Published：15 February 2025
- 稿件说明：
移动端阅览
袁思晗,蒋蓉,郑妤婕,等.欧盟患者药品说明书管理体系研究及启示[J].中国药房,2025,36(03):269-274.

YUAN Sihan,JIANG Rong,ZHENG Yujie,et al.Study on patients’ medicine instruction regulatory system in the European Union and the enlightenment[J].ZHONGGUO YAOFANG,2025,36(03):269-274.
袁思晗,蒋蓉,郑妤婕,等.欧盟患者药品说明书管理体系研究及启示[J].中国药房,2025,36(03):269-274. DOI： 10.6039/j.issn.1001-0408.2025.03.02.

YUAN Sihan,JIANG Rong,ZHENG Yujie,et al.Study on patients’ medicine instruction regulatory system in the European Union and the enlightenment[J].ZHONGGUO YAOFANG,2025,36(03):269-274. DOI： 10.6039/j.issn.1001-0408.2025.03.02.

摘要

目的

为建立与完善我国患者药品说明书管理体系提供参考。

方法

通过检索欧洲药品管理局（EMA）官方网站及相关文献，介绍欧盟患者药品说明书的定义、基本性质与项目内容，从专职管理部门设置、审批与变更程序、内容可读性、信息可及性方面分析欧盟患者药品说明书管理体系的特点；同时，分析我国患者药品说明书试点情况以及分类管理路径、内容可读性与信息时效性方面存在的问题，并提出建议。结果与

结论

欧盟设有药品说明书专职管理部门；患者药品说明书审批与变更程序清晰，内容可读性要求详细，建立有患者参与的可读性验证程序，采取多渠道且及时的信息公开形式。建议我国建立专业人士药品说明书与患者药品说明书分类管理机制；引导多方参与患者药品说明书设计，细化可读性要求；健全药品说明书信息公开机制，提高用药信息时效性。

Abstract

OBJECTIVE

To provide reference for the establishment and improvement of the regulatory system of patients’ medicine instructions in China.

METHODS

Through searching the official website of the European Medicines Agency （EMA） and related literature， the definition， basic nature， and content of patients’ medicine instructions in the European Union were introduced， and the characteristics of the management system of patients’ medicine instructions in the European Union were analyzed in terms of the management department， approval and change procedures， readability requirements and information accessibility requirements. At the same time， the pilot situation of patients’ medicine instructions in China， as well as problems in the paths of classification and management， readability of content， and information timeliness were analyzed to put forward suggestions.

RESULTS &CONCLUSIONS

European Union had a dedicated department for the management of medicine instructions； the approval and change procedures for patients’ medicine instructions were clear， the readability requirements were detailed， the readability verification program with patient participation was established， and multi-channel and timely information disclosure was adopted. It is recommended that China establish a mechanism to categorize and manage professionals’ and patients’ medicine instructions， guide multiple parties to participate in the design of patients’ medicine instructions and refine the readability requirements， and improve the mechanism for disclosure of medicine instructions to enhance the timeliness of medication information.

关键词

Keywords

references

吴文宇，林小嫚，刘锐，等 . 深圳市居民使用药品说明书情况及其影响因素研究 [J ] . 中国健康教育， 2024 ， 40 （ 4 ）： 357 - 361 .

WU W Y ， LIN X M ， LIU R ， et al . A study on use of drug inserts and its influencing factors among residents in Shenzhen City [J ] . Chin J Health Educ ， 2024 ， 40 （ 4 ）： 357 - 361 .

谈澍，邢花 . 深圳居民对药品说明书的认知状况调查 [J ] . 中国医药指南， 2023 ， 21 （ 32 ）： 43 - 46 .

TAN S ， XING H . Survey of Shenzhen residents’ cognition of drug package inserts [J ] . Guide China Med ， 2023 ， 21 （ 32 ）： 43 - 46 .

闫盈盈，何娜，张志玲，等 . 生成式人工智能构建患者药品说明书的方法研究 [J ] . 临床药物治疗杂志， 2024 ， 22 （ 5 ）： 1 - 6 .

YAN Y Y ， HE N ， ZHANG Z L ， et al . Methods for constructing patient medication instructions using generative artificial intelligence [J ] . Clin Med J ， 2024 ， 22 （ 5 ）： 1 - 6 .

国家药品监督管理局 . 国家药监局关于发布药品说明书适老化及无障碍改革试点工作方案的公告 [EB/OL ] .（ 2023-10-31 ）[ 2024-06-01 ] . https：//www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20231031153424162.html https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20231031153424162.html .

NMPA . Notice of NMPA on issuing the tasks for pilot reform of the age-friendly and barrier-free drug labeling [EB/OL ] .（ 2023-10-31 ）[ 2024-06-01 ] . https：//www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20231031153424162.html https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20231031153424162.html .

董淑杰，翟所迪 . 国外患者用药说明书的设计与实践概述 [J ] . 中国药物应用与监测， 2013 ， 10 （ 4 ）： 227 - 231 .

DONG S J ， ZHAI S D . A review of design and practice of patient medication information in foreign countries [J ] . Chin J Drug Appl Monit ， 2013 ， 10 （ 4 ）： 227 - 231 .

EMA . Centralised procedures：quality review of documents （QRD） templates [EB/OL ] .（ 2024-02-29 ）[ 2024-06-01 ] . https：//www.ema.europa.eu/en/human-regulatory-overview/marketing-authorisation/product-information-requirements/product-information-templates-human https://www.ema.europa.eu/en/human-regulatory-overview/marketing-authorisation/product-information-requirements/product-information-templates-human .

EMA . Pre-authorisation guidance：how long does it take for my application to be evaluated? [EB/OL ] .（ 2024-06-30 ）[ 2024-12-08 ] . https：//www.ema.europa.eu/en/human-regulatory-overview/marketing-authorisation/pre-autho-risation-guidance#51-procedure-6901 https://www.ema.europa.eu/en/human-regulatory-overview/marketing-authorisation/pre-autho-risation-guidance#51-procedure-6901 .

王艳文 . 我国药品说明书监管体系的初步研究 [D ] . 郑州：郑州大学， 2022 .

WANG Y W . A preliminary study on the regulatory system of drug labels in China [D ] . Zhengzhou ： Zhengzhou University ， 2022 .

马倩，周天爱，张清，等 . 多信息来源背景下药品说明书上市后变更的统一和协调 [J ] . 中国食品药品监管， 2022 （ 7 ）： 38 - 49 .

MA Q ， ZHOU T A ， ZHANG Q ， et al . Unification and coordination of post-marketing drug labeling changes under the background of multiple information sources [J ] . China Food Drug Adm Mag ， 2022 （ 7 ）： 38 - 49 .

EMA . Guideline on the readability of the labelling and package leaflet of medicinal products for human use [EB/OL ] .（ 2009-01-12 ）[ 2024-06-01 ] . https：//www.ema.europa.eu/en/human-regulatory-overview/marketing-authorisation/pre-authorisation-guidance https://www.ema.europa.eu/en/human-regulatory-overview/marketing-authorisation/pre-authorisation-guidance .

汤韧，王晓燕，杨悦 . 欧美非处方药药品说明书可读性测试简介及启示 [J ] . 中国药物警戒， 2013 ， 10 （ 8 ）： 464 - 467 .

TANG R ， WANG X Y ， YANG Y . Brief introduction and implication of the package leaflet readability guidelines of FDA and EMA [J ] . Chin J Pharmacovigil ， 2013 ， 10 （ 8 ）： 464 - 467 .

张伊楠，吴汀溪，赵志刚 . 美国、欧盟和我国监管部门对药品获益-风险沟通管理与实践的研究 [J ] . 药物流行病学杂志， 2024 ， 33 （ 1 ）： 19 - 27 .

ZHANG Y N ， WU T X ， ZHAO Z G . National competent authority regulation and practice of drug benefit-risk communication in the United States，European Union and China [J ] . Chin J Pharmacoepidemiol ， 2024 ， 33 （ 1 ）： 19 - 27 .

郑妤婕，蒋蓉，陈艺瑄，等 . 电子药品说明书的国际实践及经验启示 [J ] . 中国药房， 2024 ， 35 （ 17 ）： 2061 - 2067 .

ZHENG Y J ， JIANG R ， CHEN Y X ， et al . International practice and experience insights of electronic drug instructions [J ] . China Pharm ， 2024 ， 35 （ 17 ）： 2061 - 2067 .

唐菀晨，由玉伟，陆颖，等 . 通过共建共治方式解决药品说明书信息公开、更新和应用问题研究 [J ] . 中国药事， 2023 ， 37 （ 8 ）： 890 - 896 .

TANG W C ， YOU Y W ， LU Y ， et al . Study of solving the problems of information disclosure，update and application of drug labels by constructing a co-governance system [J ] . Chin Pharm Aff ， 2023 ， 37 （ 8 ）： 890 - 896 .

Views

156

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Analysis of influential factors for potentially inappropriate medication in elderly cancer patients

高危药品分级管理模式探讨

我院医院信息系统的改进及合理用药监控软件的应用

浅析我国农村用药安全现状、存在的问题与对策

我院2159例调剂内部差错帕累托图构成分析

Related Author

FANG Jinman

ZHANG Mei

ZHU Wenjing

HUANG Lingling

WANG Junping

张婷马丽萍马罡孙正圆张晓乐

董松飞徐昕

刘军陈丹镝张龙李凯

Related Institution

Center of Pharmacy， Hefei Cancer Hospital， Chinese Academy of Sciences

Dept. of Gastrointestinal Surgery， Hefei Cancer Hospital， Chinese Academy of Sciences

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰